Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation

Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company’s Volt system and future glucose-ketone monitoring technology.

Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse’s uptake has been “subdued” despite price parity with Farapulse, according to Oppenheimer.

Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation

Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company’s performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in “significant gains” in electrophysiology.

The second driver is Abbott’s glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.